PRN: Breast Cancer is Most Productive Pipeline with 1,050 Drugs in Development, says GBI Research

01/mar/2016 14.03.08 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Breast Cancer is Most Productive Pipeline with 1,050 Drugs in Development, says GBI Research

 
[01-March-2016]
 

LONDON, March 1, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Frontier Pharma: Breast Cancer - states that the breast cancer treatment pipeline's exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages, may significantly alter the clinical and commercial landscape of the disease market over the next decade.

The factors driving such innovation and potential for breakthrough drugs include a very large and growing patient pool, a well-established market with multiple unmet needs, and a robust understanding of the disease pathophysiology, facilitating the development of novel compounds that may fill such needs.

Managing Analyst Dominic Trewartha says: "Breast cancer has the largest product pipeline in the pharmaceutical industry, and its significant patient population and successful commercialization of drugs such as Herceptin have attracted a great deal of R&D investment.

"The sheer number of first-in-class products in development reflects a deepening scientific understanding of the underlying pathophysiology of breast cancer and a growing list of molecules that have been implicated in the initiation and progression of the disease.

"Although the development of products for novel molecular targets is risky, as their role in disease pathophysiology is often poorly characterized, the breast cancer pipeline also has the potential to yield therapies that outperform existing products and mechanisms of action."

GBI Research also states that while the cure rate for early-stage breast cancer is currently high, more advanced forms of the disease, such as metastatic cancer, are not so treatable.

Trewartha explains: "Due to the highly complex and polygenic nature of breast cancer, it is unlikely that the inhibition of a single target will be sufficient to substantially improve the prognosis in the clinic.

"However, it is far more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, will be able to do this, which will positively change the clinical landscape."

Sample pages of GBI Research's report Frontier Pharma: Breast Cancer are available upon request

 About GBI Research

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter

For more information about our offerings, please contact us on:

+44(0)161-359-5817

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl